Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410434 | 0.78 | FFAR4 (0.43) | FFAR4MCHR1HDAC1HDAC8HDAC6 | |
| SCHEMBL1410200 | 0.76 | DPP4 (0.45) | FFAR4DPP4NOTUM | |
| SCHEMBL1410394 | 0.75 | MCHR1 (0.37) | FFAR4MCHR1AKR1C3AKR1C2HDAC1 | |
| SCHEMBL1409429 | 0.75 | FFAR4 (0.39) | FFAR4MCHR1AKR1C3AKR1C2HDAC1 | |
| SCHEMBL11747518 | 0.72 | FFAR4 (0.42) | FFAR4MCHR1HDAC1HDAC8HDAC6 | |
| SCHEMBL2517777 | 0.70 | AKR1C3 (0.32) | FFAR4AKR1C3AKR1C2 | |
| SCHEMBL1410243 | 0.69 | NOTUM (0.57) | NOTUM | |
| SCHEMBL1409630 | 0.68 | FFAR4 (0.42) | FFAR4MCHR1HDAC1HDAC8HDAC6 | |
| SCHEMBL1410285 | 0.67 | FFAR4 (0.41) | FFAR4MCHR1HDAC1HDAC8HDAC6 | |
| SCHEMBL1410358 | 0.66 | FFAR4 (0.48) | FFAR4DPP4NOTUMCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | FFAR4 4589/4885MCHR1 2194/4885AKR1C3 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.